GlassScriptPhysician profile
James Y Tsai
NPI 1437152857
$3,372.42
in general payments reported to CMS, 2019-2025
37 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $428 · 2021: $492 · 2022: $428 · 2023: $322 · 2024: $280 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714 · Education: $91.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.84 |
| Education | $91.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $366.68 | 2019-2025 | Rybrevant, Erleada, Balversa |
| E.R. Squibb & Sons, L.L.C. | $290.31 | 2019-2023 | Opdivo |
| Amgen INC. | $215.30 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.20 | 2019-2024 | Fruzaqla, Alunbrig |
| Novartis Pharmaceuticals Corporation | $194.75 | 2019-2024 | |
| Pfizer INC. | $185.88 | 2019-2024 | |
| Celgene Corporation | $179.99 | 2019-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $146.63 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $140.85 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.70 | 2019-2023 | |
| Karyopharm Therapeutics INC. | $125.00 | 2023-2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $109.75 | 2019 | |
| Abbvie INC. | $109.71 | 2023-2024 | Venclexta, Dalvance |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Daiichi Sankyo INC. | $85.07 | 2019-2024 | Enhertu |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $76.92 | 2019-2020 | |
| Gilead Sciences, INC. | $62.99 | 2019-2021 | |
| Array Biopharma INC | $62.32 | 2022-2024 | Mektovi, Xalkori, Braftovi |
| Beigene USA, INC. | $53.45 | 2020-2021 | |
| Kite Pharma, INC. | $48.95 | 2021-2023 | Yescarta |
| Eisai INC. | $47.74 | 2022-2023 | |
| Epizyme, INC. | $45.00 | 2021 | |
| Genzyme Corporation | $42.73 | 2019 | |
| Genentech USA, INC. | $38.39 | 2019-2024 | Phesgo |
| Puma Biotechnology, INC. | $38.36 | 2019-2021 | |
| Incyte Corporation | $32.83 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $27.86 | 2019 | |
| Tesaro, INC. | $26.27 | 2019 | |
| Springworks Therapeutics, INC. | $26.04 | 2024 | Ogsiveo |
| Glaxosmithkline, LLC. | $22.33 | 2021 | |
| Foundation Medicine, INC. | $21.74 | 2020 | |
| Myovant Sciences INC. | $21.68 | 2021 | |
| Emd Serono, INC. | $21.40 | 2019 | |
| Therapeuticsmd, INC. | $19.20 | 2020 | |
| West Therapeutics Development, LLC | $18.13 | 2019 | |
| Acrotech Biopharma INC. | $17.29 | 2024 | Beleodaq |
| Morphosys, US INC. | $17.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.